Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Bevacizumab 39Paclitaxel 35pembrolizumab 27Carboplatin 27Specimen Handling 21olaparib 19Magnetic Resonance Spectroscopy 19Gemcitabine 19liposomal doxorubicin 17Cyclophosphamide 16niraparib 13fludarabine 12Topotecan 12Cisplatin 12Biopsy 12Taxes 9Nivolumab 8Immunoglobulin G 8Fulvestrant 8Doxorubicin 8Disulfides 8Surveys and Questionnaires 7palbociclib 6aldesleukin 6Oxaliplatin 6Letrozole 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ovarian Neoplasms × mirvetuximab soravtansine × 90 days × Clear all
NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

University of Colorado, Denver

Phase 2 Recruiting
53 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07059845 2026-06-04

FLORENZA

AbbVie

Phase 2 Recruiting
400 enrolled
Gynecologic

Ovarian Neoplasms

NCT05445778 2026-06-02

GLORIOSA

AbbVie

Phase 3 Active not recruiting
520 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06365853 2026-03-25

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

AbbVie

Phase 2 Recruiting
100 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡